Focus

In-Depth Oncology Cohort Analysis

Get access to curated patient data for a specific sub population to guide go/ no-go decisions, inform study design, and develop ECAs to support regulatory submission.

Group 48
Use Cases

Uncover Patterns in Targeted Populations to Drive Commercial Strategy

Our Focus product is a highly customized, enriched real-world patient data package designed to support your specific research objectives.

Support Rare-Cohort Label Expansions

Focus data can be tailored to specific patient cohorts to support ancilliary approval submissions for small populations.

Investigate Outcomes for Specific Subpopulations

Conduct Phase IV and HEOR studies to identify patterns in treatment response for specific patient sub cohorts.

Group 207

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Quality Real-World Data for Hematologic and Solid Tumor Diagnoses

COTA’s database of patients includes longitudinal treatment and outcomes data for oncology patients including:

Heme/Onc:

Solid Tumors:

Group 127
Group 203
Additional Support

Get the Most of Your Focus Data with Real-World Insights and Support

Real-World Insights and Support is an optional add-on that pairs perfectly with your Focus data. Our team of clinical experts, researchers, and statisticians will come alongside your teams to help them use the data to design studies, run analyses, and construct regulatory submission packages.

Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

Group 134 (1)

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading...

Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence

Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc.,...

COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients

For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power...

Put Your Data into Focus

Discover the power of real-world cancer data to help you answer questions about specific patient subpopulations.

Group 11